Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.

This is an important and interesting multicenter international randomized placebo-controlled dose-escalating study looking at the safety and efficacy of using rFVIIa following intracerebral hemorrhage (ICH). Patients received placebo or one dose of rFVIIa within 4 hours of onset of symptoms after CT-proven intracranial hemorrhage. There was no significant difference in change of volume of ICH between groups, neither the incidence and severity of adverse events. A larger similar multicenter study is ongoing to determine whether rFVIIa is effective in limiting ICH growth.

– Maadh Aldouri